Page 108 - 2019_11 Resto del Mondo-web

S. Claudiani et al.
17. Iacobucci I, Saglio G, Rosti G, et al.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12(10):3037-3042.
18. Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: impor- tance of a stable molecular response. Clin Cancer Res. 2009;15(3):1059-1063.
19. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytoge- netic response. J Clin Oncol. 2009;27(22): 3659-3663.
20. Foroni L, Wilson G, Gerrard G, et al. Guidelines for the measurement of BCR- ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol. 2011;153(2):179- 190.
21. Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program. 2007:376-383.
22. Carrera PM, Kantarjian HM, Blinder VS. The
financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2): 153-165.
23. Clark RE, Polydoros F, Apperley JF, et al. De- escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DES- TINY): an interim analysis of a non-ran- domised, phase 2 trial. Lancet Haematol. 2017;4(7):e310-e316.
24. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
25. Druker BJ, Guilhot F, O'Brien SG, et al. Five- year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
26. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112(4):837-845.
27. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or
suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual out- come is poor. Blood. 2008;112(12):4437- 4444.
28. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-ran- domised, trial. Lancet Oncol. 2018;19 (6):747-757.
29. Claudiani S, Apperley JF, Gale RP, et al. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remis- sion in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica. 2017;102(8):e297-e299.
30. Etienne G, Guilhot J, Rea D, et al. Long- Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017;35 (3):298-305.
31. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-854.
2214
haematologica | 2019; 104(11)